Patent 9249226 was granted and assigned to Genmab A/S on February, 2016 by the United States Patent and Trademark Office.
Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.